Considerations for a Pan-African HIV Vaccine Development Agenda

16 – 17 March 2015

Location

Kivu Ballroom
Hôtel des Mille Collines by Kempinski
Kigali, Rwanda

Background and objectives

Support development of a pan-African HIV vaccine agenda and facilitate strategic planning ensuring development of vaccine strategies for all populations in need.

Various groups are advancing different vaccine strategies, including subtype neutral designs for global use, expected to be successful against most or all subtypes of HIV. This diversity of strategies provides an opportunity to review and discuss the vaccine pipeline, burden of disease in the different African regions, existing African cohorts with high enough incidence for future efficacy trials, and ways forward to determine how broad or narrow protection, if observed, will be. The meeting will discuss the optimal design of initial efficacy trials and potentially bridging studies to ensure the broadest possible benefit of candidates in regions that didn’t participate in a successful efficacy trial, since widespread use will need to be expedited when deployable results are obtained.

Agenda

Meeting chairs – Pontiano Kaleebu, MRC/UVRI Uganda Research Unit on AIDS and Sabin Nsanzimana, Rwanda Biomedical Center

DAY 1 - 16 MARCH 2015

8:30 – 9:00 Welcome and meeting objectives – Pontiano Kaleebu, MRC/UVRI Uganda Research Unit on AIDS, Uganda

9:00 – 9:15 Welcome to Rwanda – Honorable Minister Dr. Agnes Binagwaho, Minister of Health, Rwanda

9:15 – 10:00 The Vaccine Pipeline
Moderators: Pat Fast, International AIDS Vaccine Initiative and Hannah Kibuuka, Makerere University Walter Reed Project
- Global pre-clinical data and new vaccine concepts: Anna-Lise Williamson, University of Cape Town, South Africa
- Mosaic approaches: Hanneke Shuitemaker, Crucell, Netherlands
- Conserved approaches: Pat Fast, IAVI, USA
10:00 – 10:30  Break

10:30 - 12:00  The Vaccine Pipeline (continued)
Moderators: Pat Fast, International AIDS Vaccine Initiative and Hannah Kibuuka, Makerere University Walter Reed Project
  o  Gates Foundation vaccine pipeline: Silvija Staprans, Bill & Melinda Gates Foundation, USA
  o  P5 and HVTN trial plans in Southern Africa: Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory, South Africa
  o  Trial design considerations: Eric Sandstrom, Karolinska Institutet, Sweden and Anatoli Kamali, MRC/UVRI Uganda Research Unit on AIDS, Uganda
  o  General panel discussion: All

12:00 – 13:00  Lunch at La Terrasse Restaurant

13:00 – 14:30  Assays and lab endpoints
Moderators: Omu Anzala KAVI - Institute of Clinical Research, University of Nairobi and Muhammad Bakari, Muhimbili University of Health and Allied Sciences
  o  Safety tests, quality systems-accreditation, QC, QA, monitoring, and capacity building: Fatim Jallow, Makerere University Walter Reed Project, Uganda
  o  Immunogenicity and research assays: Jill Gilmour, IAVI, USA and Erica Andersen-Nissen, Cape Town HVTN Immunology Laboratory, South Africa
  o  General panel discussion: All

14:30 – 15:00  Break

15:00 – 17:00  Diversity of the epidemic in Africa
Moderators: Etienne Karita, Projet San Francisco and Thumbi Ndung’u, University of KwaZulu-Natal
Presenters to address host (HLA, gender, weight) and viral factors (diversity, sequence, immune responses) by region
  o  East Africa – Kayvon Modjarrad, World Health Organization, Switzerland
  o  West Africa – Marcel Tongo, International Centre for Genetic Engineering and Biotechnology, University of Cape Town, South Africa
  o  Southern Africa – Carolyn Williamson, University of Cape Town and National Health Laboratory, South Africa
  o  Replicating capacity – William Kilembe, Zambia-Emory HIV Research Project, Zambia
  o  General panel discussion: All

19:00  Dinner at Le Panorama Restaurant
## DAY 2 – 17 MARCH 2015

### 8:30 – 10:00  Cohorts and capacity

Moderators: Gaudensia Mutua, KAVI - Institute of Clinical Research, University of Nairobi and Fred Sawe, Kenya Medical Research Institute / Walter Reed Project

- **Kayvon Modjarrad** on behalf of ‘Jide Keshinro, Military HIV Research Program, Nigeria, USA
- **Joshua Kimani**, University of Nairobi/Manitoba Kenya
- **Elizabeth Bukusi**, Kenya Medical Research Institute, Kenya and **Anatoli Kamali**, UVRI-IAVI HIV Vaccine Program, Uganda
- **Susan Allen**, Department of Pathology and Laboratory Medicine Rwanda Zambia HIV Research Group School of Medicine Emory University, USA

**General panel discussion: All**

### 10:00 – 10:30  Break

### 10:30 – 12:00  Regulatory Considerations

Moderators: Thomas Nyirenda, European and Developing Countries Clinical Trials Partnership and Dean Smith, Health Canada

- **AVAREF: David Mukanga**, Gates Foundation, USA and **Beno Yakubu**, National Agency for Food and Drug Administration and Control, Nigeria
- **Tusubira Evans**, National Drug Authority, Uganda

**General panel discussion: All**

### 12:00 – 13:00  Lunch at La Terrasse Restaurant

### 13:00 – 15:00  Facilitated discussion

Moderators: Pontiano Kaleebu, MRC/UVRI Uganda Research Unit on AIDS and Sabin Nsanzimana, Rwanda Biomedical Center

- One moderator of each session to summarize main points of discussion
- Synthesis of discussion and identified needs and opportunities
- Development of preliminary list of scientific priorities and possible future activity

### 15:00 – 15:30  Recommendations and next steps

Pontiano Kaleebu, MRC/UVRI Uganda Research Unit on AIDS and Sabin Nsanzimana, Rwanda Biomedical Center

### 15:30  Reception at La Terrasse Restaurant